RYTM – rhythm pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline [Yahoo! Finance]
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $50.00 price target on the stock.
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Cramer's Lighting Round: Sell Aspen Aerogels [CNBC]
Form SC 13D/A RHYTHM PHARMACEUTICALS, Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
Form ARS RHYTHM PHARMACEUTICALS, For: Dec 31
Form DEFA14A RHYTHM PHARMACEUTICALS,
Form DEF 14A RHYTHM PHARMACEUTICALS, For: Jun 18
Form SC 13D/A RHYTHM PHARMACEUTICALS, Filed by: PERCEPTIVE ADVISORS LLC
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.